Gilead-Supported Abstracts Published at CROI 2021: Treatment Updates and Lenacapavir Advancements
Abstracts from CROI 2021 selected by Gilead highlight treatment effects on neurologic outcomes, drug interactions, clinical trials of antiretroviral therapy, and new developments in drug resistance. Additionally, the session on Lenacapavir (GS-6207) presents promising data on this long-acting HIV capsid inhibitor. Explore the latest research and advancements in HIV treatment and prevention.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Gilead-initiated or Gilead-supported Abstracts Published at CROI 2021 Abstracts selected by Gilead Medical Affairs Germany, March 6th 1
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts B/F/TAF Session Information Link to Presentation Oral / Poster Presenter Title Science Spotlights TREATMENT EFFECTS ON NEUROLOGIC OUTCOMES -F4 Alessandra Vergori Impact of switch from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition Poster 334 Link Science Spotlights DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT -G3 Drug interactions with once-daily B/F/TAF in combination with once-weekly rifapentine Poster 369 Priyanka Arora Link Science Spotlights CLINICAL TRIALS OF ANTIRETROVIRAL THERAPY: TREATMENT NAIVE AND SWITCH Science Spotlights NEW DEVELOPMENTS IN TRANSMITTED AND ACQUIRED DRUG RESISTANCE -H6 Kimberly Workowski Poster 415 4-Year outcomes of B/F/TAF in treatment-na ve adults Link -I2 HIV with transmitted drug resistance is durably suppressed by B/F/TAF at week 144 Poster 430 Rima K. Acosta Link Michelle L. D'Antoni Science Spotlights NEW RESISTANCE TECHNOLOGIES -I3 Poster 438 HIV-1 DNA genotyping is often variable in repeat testing from single blood draws Link 2
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Lenacapavir (LEN, GS-6207) Session Information Symposium-01 NAVIGATING TO THE NUCLEUS Monday, March 8 ON-DEMAND released on Monday Oral Abstract-06 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV Tuesday, March 9 18:35 18:45 CET Oral Abstract-06 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV Tuesday, March 9 18:45 18:55 CET Oral Abstract-02 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND ART Monday, March 8 17:40 17:50 CET Link to Presentation Oral / Poster Presenter Title Lenacapavir (GS-6207): First clinically active long-acting inhibitor of HIV Capsid Symposium Tomas Cihlar Link Sorana Segal- Maurer Potent antiviral activity of Lenacapavir in phase 2/3 in heavily ART- experienced PWH Oral 127 Link Laurie VanderVeen Activity and resistance characterization of the HIV Capsid inhibitor Lenacapavir Oral 128 Link Clinical evaluation of drug interactions with oral Lenacapavir and probe drugs Oral 89 Justin Lutz Link Science Spotlights NEW APPROACHES TO OPTIMIZE DRUG DOSING: LONG ACTING AND BEYOND -G4 Vamshi JogirajuPharmacokinetics of Lenacapavir, an HIV-1 Capsid inhibitor, in hepatic Poster 375 Link impairment Late Breaker Poster 717 Long-acting HIV Capsid inhibitor effective as PrEP in a SHIV rhesus macaque model Science Spotlights NEW PrEP AGENTS AND FORMULATIONS -V3 Elena Bekerman Link 3 See also Gilead-independent abstract: Poster 420 from Bester et al. Structural basis for viral resistance to long-acting HIV-1 capsid inhibitor GS-6207. Link
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts HIV Treatment 1 of 2 Session Information Oral Abstract-10 HIV RESERVOIRS Wednesday, Mar 10 17:20 17:30 CET Oral Abstract-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES Wednesday, Mar 10 17:30 17:40 CET Oral Abstract-12 MATERNAL AND CHILD HIV AND SARS-CoV-2 Wednesday, Mar 10 18:35 18:45 CET Science Spotlights EFFECTS OF DRUG DISPOSITION IN THE CSF, LYMPH NODES, LUNG, AND GENITAL TRACT Link to Presentation Oral / Poster Presenter Title Infected cells are clonotypically diverse in blood & lymph nodes since Fiebig stage I Oral 154 Pierre Gantner Link Napapon Sailasuta 3T brain MRS reveals distinct metabolite patterns of ART initiation during acute HIV Oral 163 Link Late Breaker Oral 177 Lameck ChinulaSafety/efficacy of DTG vs EFV, TDF vs TAF in pregnancy/postpartum: IMPAACT Link 2010 trial -G2 Courtney V. Fletcher Poster 359 Persistent HIV transcription and variable ARV levels in lymph nodes during ART Link Science Spotlights ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES -H5 Effectiveness of recommended 3-drug regimens for treating advanced HIV infection Poster 406 Karam Mounzer Link Science Spotlights ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES -H5 Bharat Nandakumar Blip incidence in Dolutegravir- or Efavirenz-based ART during acute HIV infection Poster 407 Link 4
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts HIV Treatment 2 of 2 Session Information Link to Presentation Oral / Poster Presenter Title Science Spotlights ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES -H5 HMMCgag assay detects high viremia rates on ART started during acute HIV infection Poster 408 Donn J. Colby Link Science Spotlights MODELING HIV OUTCOMES -R6 Poster 672 Robert Paul Predictive models of ART responses among acutely infected individuals Link Science Spotlights DISPARITIES AND STRUCTURAL FACTORS AFFECTING HIV CARE OUTCOMES -R4 Poster 657 Tonia Poteat Housing and HIV outcomes among transgender women in South Africa Link 5
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Comorbidities 1 of 2 Session Information Oral Abstract-07 TUBERCULOSIS AND HEPATITIS Tuesday, Mar 9 18:25 18:35 CET Link to Presentation Oral / Poster Presenter Title Sunil S. Solomon A simple and safe approach to HCV treatment: Findings from the A5360 (MINMON) trial Oral 135 Link Science Spotlights BIOMARKERS AND NEUROCOGNITIVE STATUS -F2 Baseline monocyte HIV RNA predicts blunted cognitive trajectories in acute infection Poster 323 Ivo SahBandar Link Science Spotlights TREATMENT EFFECTS ON NEUROLOGIC OUTCOMES -F4 Poster 340 Phillip Chan Stable improvement in depression 6 years after ART initiation during acute HIV Link Science Spotlights HCV: THERAPEUTICS AND PROGRESS TOWARD ELIMINATION -J1 Christoph Boesecke Poster 439 Reinfection with the hepatitis C virus in men who have sex with men Link Science Spotlights HCV: THERAPEUTICS AND PROGRESS TOWARD ELIMINATION -J1 No change in incidence of recently acquired HCV in HIV+ MSM in Germany (NoCo Cohort) Poster 442 Patrick Ingiliz Link Science Spotlights BIOMARKERS OF INFLAMMATION, ART, AND ATHEROSCLEROSIS OR CARDIOVASCULAR DISEASE -L1 Bastian Neesgaard Association between integrase inhibitors (InSTIs) and cardiovascular disease (CVD) Poster 488 Link 6
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Comorbidities 2 of 2 Session Information Link to Presentation Oral / Poster Presenter Title Science Spotlights GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV -L2 Late Breaker Poster 494 Steven Grinspoon Coronary artery disease, traditional risk, and inflammation among PWH in REPRIEVE Link Science Spotlights GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV -L2 Markella V. Zanni Poster 496 Factors associated with systemic immune activation in a global HIV cohort Link Science Spotlights GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV -L2 Poster 498 Kathleen Fitch Diet quality by global burden of disease region in PWH in the REPRIEVE trial Link Science Spotlights INFLAMMATION AND COMORBIDITIES DURING ART -M4 Sergio Serrano- Villar Poster 527 Effects of switch from 3DR to 2DR on inflammatory biomarkers Link Science Spotlights RENAL AND BONE DISEASES -M6 Poster 540 Frank A. Post Safety of TAF in patients with a history of proximal renal tubulopathy on TDF Link 7
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Comorbidities Weight Change Session Information Oral Abstract-12 Link to Presentation Oral / Poster Presenter Title Risa M. Hoffman Antepartum weight gain and adverse pregnancy outcomes in IMPAACT 2010 MATERNAL AND CHILD HIV AND SARS-CoV-2 Wednesday, Mar 10 18:25 18:35 CET Oral 176 Link Grace A. McComsey Weight gain after switching different integrase strand transfer inhibitors (InSTIs) Science Spotlights GAIN DURING ART -M1 WEIGHT Link Poster 503 Loveleen Bansi- Matharu Association between newer antiretrovirals and increase in body mass index in RESPOND Science Spotlights GAIN DURING ART -M1 WEIGHT Poster 507 Link Assessment of obesity and metabolic profile by integrase inhibitor use in REPRIEVE Science Spotlights GAIN DURING ART -M1 WEIGHT Poster 506 Janet Lo Link Urine mitochondrial DNA, weight loss, and body composition in older adults with HIV Science Spotlights GAIN DURING ART -M1 WEIGHT Poster 513 Carrie Johnston Link Predicted 10-year risks of cardiovascular disease and diabetes in the ADVANCE trial Science Spotlights DIABETES DURING ART -M2 TYPE 2 Poster 517 Laura Hindley Link Science Spotlights COMORBIDITIES IN PREGNANT WOMEN WITH HIV -P2 CHRONIC Evangelia E. Baxevanidi Predicted long-term adverse birth and child health outcomes in the ADVANCE trial Poster 572 Link 8
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Prevention 1 of 3 Session Information Oral Abstract-09 PREVENTION 2021 Tuesday, Mar 9 17:40 17:50 CET Oral Abstract-09 PREVENTION 2021 Tuesday, Mar 9 17:50 18:00 CET Oral Abstract-09 PREVENTION 2021 Tuesday, Mar 9 18:15 18:25 CET Oral Abstract-09 PREVENTION 2021 Tuesday, Mar 9 18:35 18:45 CET Oral Abstract-09 PREVENTION 2021 Tuesday, Mar 9 18:45 18:55 CET Oral Abstract-13 INNOVATIONS AND CHALLENGES IN TESTING, PREVENTION, AND CARE Wednesday, Mar 10 17:20 17:30 CET Link to Presentation Oral / Poster Presenter Title Jean-Michel Molina Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France Oral 148 Link Dvora L. Joseph Davey Impact of common side effects on PrEP persistence during pregnancy in South Africa Oral 149 Link Oral 150 Anne M. Neilan Cost-effectiveness of long-acting PrEP among MSM/TGW in the US Link HSV-2 acquisition in a randomized trial of contraceptive methods among African women Oral 152 Nelly R. Mugo Link Late Breaker Oral 153 Raphael J. Landovitz Laboratory analysis of HIV infections in HPTN 083: Injectable CAB for PrEP Link PrEP use during acute HIV infection in a community setting compromises HIV diagnosis Oral 179 Donn J. Colby Link 9
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Prevention 2 of 3 Session Information Link to Presentation Oral / Poster Presenter Title Matthew Spinelli Science Spotlights ADVANCES IN ADHERENCE TESTING -G1 Poster 354 Establishing the cut-off for a urine-based point-of-care test for adherence to TAF Link Science Spotlights EFFECTS OF DRUG DISPOSITION IN THE CSF, YMPH NODES, LUNG, AND GENITAL TRACT -G2 Carolina Herrera Pharmacokinetic and pharmacodynamic study of TFV and TAF for PrEP in foreskin tissue Poster 361 Link Science Spotlights DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT -G3 Exogenous hormone pharmacokinetics in transgender adolescents receiving oral TDF/FTC Poster 366 Jenna L. Yager Link Science Spotlights DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT -G3 TFV-DP and FTC-TP in PBMC among transgender adolescents receiving daily TDF/FTC Poster 367 Jenna L. Yager Link Science Spotlights NEW DEVELOPMENTS IN TRANSMITTED AND ACQUIRED DRUG RESISTANCE -I2 Poster 428 Stephanie Cox Ultrasensitive HIV-1 drug resistance analysis in the DISCOVER PrEP trial Link Science Spotlights LESSONS AND CHALLENGES IN ORAL PrEP IMPLEMENTATION -V1 Poster 705 Gabriel Wagner Predictors of PrEP uptake in a sexual health clinic with immediate PrEP initiation Link 10
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Prevention 3 of 3 Session Information Link to Presentation Oral / Poster Presenter Title Science Spotlights PrEP ADHERENCE AND CONTROL OF STIs -V2 Daily doxycycline in MSM on HIV PrEP for prevention of sexually transmitted infections Poster 709 Troy Grennan Link Science Spotlights PrEP ADHERENCE AND CONTROL OF STIs -V2 Katherine M. Anderson The impact of violence on PrEP adherence among US cisgender women at risk for HIV Poster 711 Link Science Spotlights PrEP ADHERENCE AND CONTROL OF STIs -V2 Predictors of PrEP adherence and retention in US cisgender women at risk for HIV Poster 713 Jill Blumenthal Link 11
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Cure Session Information Oral Abstract-10 HIV RESERVOIRS Wednesday, Mar 10 18:45 18:55 CET Link to Presentation Oral / Poster Presenter Title Late Breaker Oral 161 Beatriz Mothe A placebo-controlled ATI trial of HTI vaccines in early treated HIV infection Link Science Spotlights HIV AND THE GUT MICROBIOME -B4 Poster 220 Yanhui Cai HIV rebound in controllers is associated with specific fecal microbiome profile Link Science Spotlights MECHANISMS OF HIV LATENCY -E2 Poster 294 Alivelu M. Irrinki Activating PKC- induces HIV expression with improved tolerability Link Science Spotlights CONTROLLERS AND POSTTREATMENT CONTROLLERS -E5 Gesham Magombedze Poster 312 Mathematical modeling of predictors of posttreatment control in HIV cure trials Link Science Spotlights NEW DRUGS, OLD DRUGS, AND NEW RESISTANCE MECHANISMS -I1 Evaluation of bnAb sensitivity by genotyping and phenotyping for HIV clinical trials Poster 425 Brian Moldt Link 12
virtual CROI 2021, 6 - 10 March 2021 Selected Gilead-initiated/supported abstracts Remdesivir (RDV) Session Information Link to Presentation Oral / Poster Presenter Title Science Spotlights SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS -H2 Poster 393 Susan Olender Remdesivir versus standard of care for severe COVID-19 Link Science Spotlights SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS -H2 Onyema Ogbuagu Acute kidney injury in patients with moderate COVID-19 treated with RDV versus SoC Poster 395 Link Science Spotlights SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS -H2 Late Breaker Poster 397 Treatment and outcomes of COVID-19 in the US: Are they different according to race? Essy Mozaffari Link Late Breaker Poster 617 Science Spotlights COVID-19 IN CHILDREN -Q5 Flor Munoz Safety and efficacy or Remdesivir in a pediatric COVID-19 population Link 13
